Work

Nanotechnology-Enabled Topical Drug Delivery for Trigeminal Neuralgia: Current Status and Future Directions

Year: 2026
Type: article
Abstract: Trigeminal neuralgia (TN) is a severely incapacitating condition marked by recurring bouts of intense, short-lived, electric shock-like face pain. In order to better characterize patients and aid in the decision-making process regarding medicinal and surgical therapies, new diagnostic criteria that subclassify TN based on the existence of trigeminal neurovascular conflict or an underlying neurological condition should be implemented. The diagnostic work-up should include MR imaging, especially high-resolution trigeminal sequences. The preferred medications are oxcarbazepine and carbamazepine. Botulinum toxin type A, baclofen, gabapentin, pregabalin, and lamotrigine can be taken either on their own or in combination with other medications. If the medicinal therapies are not well accepted or the pain is not well managed, surgery should be considered. For patients with trigeminal neurovascular conflict, trigeminal microvascular decompression is the first-line surgical procedure. If MR imaging reveals no neurovascular contact, or if patients are deemed too weak for microvascular decompression or do not want to take the risk, neuroablative surgical treatments may be available.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7235909044
FWCI:
Cites:
Cited by:
Related to: 10